RAF-265

DB05984InvestigationalSmall molecule

Investigated for use/treatment in melanoma.

Mechanism: CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms.
Curator reviewed
Primary indication: Investigated for use/treatment in melanoma.Curator reviewed
Formula / weight: C₂₄H₁₆F₆N₆O · 518.423 g/mol (avg)
Code names: CHIR-265 · NVP-RAF265 · RAF265

Resolves to

Compound

Structure

InChIKeyYABJJWZLRMPFSI-UHFFFAOYSA-NSMILESCN1C(NC2=CC=C(C=C2)C(F)(F)F)=NC2=CC(OC3=CC=NC(=C3)C3=NC=C(N3)C(F)(F)F)=CC=C12

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with RAF-265, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.